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Long QT syndrome (LQTs) is an uncommon genetic disease causing sudden car-
diac death with Torsade de Pointes (TdP). The first line drug treatment has been 
known to be β-blocker. We encountered a 15-year-old female student with LQTs 
who had prolonged QTc and multiple episodes of syncope or agonal respiration 
during sleep. Although her T wave morphology in surface electrocardiography re-
sembled LQTs type 1, her clinical presentation was unusual. During the epineph-
rine test, TdP was aggravated during β-blocker medication, but alleviated by sodi-
um channel blocker (mexiletine). Therefore, she underwent implantable 
cardioverter defibrillator implantation.
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INTRODUCTION
Long QT syndrome (LQTs) is an uncommon disease causing sudden cardiac 
death,1 and its first line treatment has been known to be β-blocker. But we experi-
enced a patient with atypical clinical presentation, which was aggravated by 
β-blocker and alleviated by mexiletine. We also report that epinephrine provoca-
tion test can play an important role in diagnosis and monitoring of drug efficiency 
in LQTs.
CASE REPORT
A 15-year-old female middle school student was referred to our hospital because 
of multiple syncopal episodes. She had experienced four syncopal episodes at 
school during the last three years. All of these episodes occurred while resting or in 
class. Her mother noticed the patient’s very unusual snoring sound with transient 
loss of consciousness twice at night, and what seemed like agonal respiration. Af-
ter that, she had palpitations with presyncope while writing in class. She had a past 
history of patch repair surgery for ventricular septal defect (VSD) at the age of 5 
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ical presentation was unusual, we stopped propranolol and 
performed an epinephrine test.
Epinephrine provocation test
After skipping propranolol for 5 times its half life, an epi-
nephrine provocation test was performed and mean QTc 
was measured after epinephrine test.2,3 Mean QTc was sig-
nificantly prolonged (637.0-48.6 ms; between 585 and 646 
ms), and frequent single or couplets of ventricular prema-
ture beats appeared (Fig. 3A). We then repeated the epi-
nephrine test with β-blocker medication. With propranolol 
120 mg per day, mean QTc was prolonged as 628.5±62.7 
ms (between 618 and 634 ms), and non-sustained polymor-
phic ventricular tachycardia (VT; 200 bpm) appeared fol-
lowing R-on-T phenomenon and spontaneously ended with-
in 8 sec without syncopal event (Fig. 3B). There were two 
different premature ventricular contraction (PVC) morphol-
ogies, and non-sustained VT initiating PVC was localized 
by 12 lead ECG (Fig. 1B). The origin of PVC seems to be 
left ventricular (LV) high septum just below the (left) distal 
HIS bundle. QRS duration is relatively narrow and purely 
negative in lead aVR and aVF, but initially positive in all oth-
er leads, suggesting LV peri-Hissian PVC related to membra-
nous VSD repair. After increasing the dosage of proprano-
lol to 160 mg per day for 3 days, sustained polymorphic VT 
was induced spontaneously, requiring external defibrilla-
tion, and syncope and tonic clonic seizure were document-
ed during the epinephrine provocation test (Fig. 3C). Mean 
QTc was prolonged as 644.0±33.7 ms (between 619 and 
668 ms). However, after stopping propranolol for 4 days, 
no arrhythmic event was reproducible during the epineph-
rine provocation test (Fig. 3D). 
Implantable cardioverter defibrillator (ICD)
Because the patient’s arrhythmia could not be controlled by 
β-blocker, she underwent ICD implantation. She returned 
to the emergency room due to ICD shock in the 3rd month 
after ICD implantation. ICD EGM documented sustained 
polymorphic VT with cycle length 220 ms and successful 
ICD therapy. Therefore, we repeated the epinephrine prov-
ocation test while medicating with mexiletine 600 mg per 
day, and there was no event except for QTc lengthening >30 
ms (Fig. 3E). She was discharged with mexiletin 600 mg 
per day and an increase in atrial pacing rate to higher than 
70 bpm. During mexiletine medication, there was no VT ep-
isode in ICD interrogation for 3 months. However, she arbi-
trarily stopped the anti-arrhythmic drug due to weakness, 
months old, however, there was no abnormality in the 
physical examination or laboratory findings, and echocar-
diography showed her heart to be completely normal mor-
phologically and functionally. The only abnormal finding 
was prolonged QTc (629 ms) in surface 12 lead electrocar-
diography (ECG) (Fig. 1A). She had no family history of 
sudden death or other genetic heart disease (Fig. 2). At the 
time when she was referred to our hospital, she was taking 
low dose of propranolol. Because ECG at the time of pre-
syncope or syncope had not been documented and her clin-
Fig. 1. (A) Baseline standard 12 lead ECG shows prolonged QTc interval 
(629 ms). (B) 12 ECG shows premature ventricular contraction which was 
originated from left ventriclular basal posteroseptum, related to earlier VSD 
repair. ECG, electrocardiography; VSD, ventricular septal defect.
Fig. 2. The genetic pedigree of the patient shows that her grandmother died 
from pancreatic cancer, and there was no family history of sudden death.
Exon 20 (G→A, R1192Q)
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ventricular tachyarrhythmia episodes.5,6 However, the drug 
failure rate of β-blocker is significantly higher in patients 
with LQTs type 3,7 and mortality and morbidity are also 
higher in LQTs type 3 than those with types 1 or 2. LQTs 
type 3 accounts for about 5-10% of LQTs.8 Nevertheless, 
β-blocker has never been reported to aggravate Torsades de 
Point (TdP) in patients with LQTs type 3. Genetically, 
LQTs type 3 has been known to be due to the mutation of 
SCN5A domain which results in a “gain of function in sodi-
um channel” and prolongs action potential duration and 
QTc. Consequently, the pharmacological blocker of sodium 
current, mexiletine, shortens the QTc interval and rescues 
the defect of the SCN5A mutation.9,10-12 However, it is not 
clear whether gene-specific medication, such as mexiletine, 
is able to prevent sudden cardiac death in patients with 
LQTs type 3. The SCN5A gene, consisting of 28 exons and 
2016 amino acids, is highly expressed in the human myo-
cardium.13 The missense, a splice-donor, or frame-shift mu-
tations in SCN5A coding regions have been known to be 
associated with Brugada syndrome, sudden infant death 
and received appropriate ICD shock 8 months after stopping 
the medication. Therefore, she is presently taking mexiletine 
600 mg a day. 
DNA isolation and genetic analysis
We genotyped 155 loci from exon 2 to 28 of the SCN5A 
gene,4 and G>A, R1192Q (rs41261344; reference sequence: 
NM000335) was identified at the exon 20 sequence. How-
ever, same base pair change was found in SCN5A genetic 
analyses in her father and siblings who did not show the 
phenotypes of LQTs (ECG or symptom) (Fig. 2). There-
fore, it seems to be genetic polymorphism in SCN5A, but 
not a mutation.
DISCUSSION
Over the past few decades, β-blocker has remained as the 
most effective medication for LQTs, functioning by short-
ening the repolarization period and reducing the duration of 
Fig. 3. The ECG documented events during epinephrine provocation test. (A) Baseline epinephrine provocation test showing non-sus-
tained VT with maximal 3 beats of extra-systole. (B) While taking propranolol 120 mg, non-sustained polymorphic VT was repeatedly doc-
umented during epinephrine infusion. (C) While taking propranolol 160 mg, torsade de pointes requiring cardioversion was spontaneously 
induced during epinephrine infusion. (D) After stopping propranolol, only isolated ventricular premature beats were induced by epineph-
rine infusion. (E) During medication with mexiletine 600 mg per day, the epinephrine provocation test showed no event except for QTc 
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syndrome, and Lev-Lenegre disease.14 
In our patient, the clinical presentation of LQTs was un-
usual (agonal respiration and syncope at rest) and the epi-
nephrine test played a remarkably important role in identify-
inggenetic subtype of LQTs and determining an appropriate 
treatment. First line drug treatment with β-blocker aggravat-
ed TdP, and mexiletine suppressed arrhythmic event in this 
patient. Without the epinephrine provocation test, β-blocker 
might have been prescribed and harmed this patient with 
life-threatening channelopathy. Although Vyas, et al.15 re-
ported low predictive value of epinephrine test in LQTs type 
3, Shimizu, et al.3 described that it still has an important di-
agnostic value in LQTs type 3. Ethnic difference or undis-
covered genetic polymorphism of SCN5A may play some 
roles in this difference. Therefore, the epinephrine test can 
be an important diagnostic and drug monitoring test, and 
complementary to genetic diagnosis. 
R1193Q has been implicated in both LQTs type 3, a gain 
of function disease,16 and in sudden unexplained nocturnal 
death syndrome, a loss of function disease.17 At the same 
time, R1193Q is considered as a polymorphism in Asians 
with an allele frequency of 8%.4,18 R1192Q in the present 
case is not distinct from R1193Q in the original hH1 se-
quence. Therefore, additional polymorphisms in SCN5A 
may contribute to R1193Q-related QTc prolongation, and we 
cannot exclude overlap phenotype of LQTs type 3 with Bru-
gada syndrome.19 
In conclusion, we experienced a patient with clinically 
type 3 LQTs who was aggravated by β-blocker and alleviat-
ed by mexiletine. The epinephrine provocation test played a 
remarkably important role in the diagnosis and monitoring 
of drug efficiency in this patient.
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